Document is current
Any future updates will be listed below
-
Authors
Tsang, Erica S. https://orcid.org/0000-0003-2317-2721
Csizmok, Veronika
Williamson, Laura M.
Pleasance, Erin
Topham, James T.
Karasinska, Joanna M.
Titmuss, Emma https://orcid.org/0000-0002-1993-6912
Schrader, Intan https://orcid.org/0000-0002-7413-4314
Yip, Stephen https://orcid.org/0000-0002-8514-9861
Tessier-Cloutier, Basile https://orcid.org/0000-0001-8739-3879
Mungall, Karen
Ng, Tony
Sun, Sophie
Lim, Howard J.
Loree, Jonathan M. https://orcid.org/0000-0001-8189-2132
Laskin, Janessa
Marra, Marco A.
Jones, Steven J. M. https://orcid.org/0000-0003-3394-2208
Schaeffer, David F.
Renouf, Daniel J. https://orcid.org/0000-0002-7597-6089
- License Information
-
More Information
Article History
Received: 8 May 2022
Accepted: 8 March 2023
First Online: 24 March 2023
Competing interests
: D.J.R. discloses research funding and honoraria from Bayer and honoraria from Servier, Celgene, Taiho, and Ipsen. Janessa Laskin declares honoraria for academic talks from Roche Canada and AstraZeneca Canada, advisory board/consultant for AstraZeneca, Boehringer-Ingelheim, Roche, Pfizer, and Takeda, and research grants from Roche Canada, Pfizer Canada, and AstraZeneca Canada. J.M.L. discloses research funding from Ipsen and consulting fees from Amgen, Eisai, Bayer, Novartis, Ipsen, Pfizer and Taiho. Stephen Yip declares member of advisory boards for Amgen, AstraZeneca, Bayer, Incyte, Novartis, and Roche. The other authors declare no potential conflicts of interest.
